Roth Capital Reaffirms TG Therapeutics (TGTX) at 'Buy'; Still Sees TGR-1202, TG-1101 as Well Positioned
Tweet Send to a Friend
Roth Capital affirms TG Therapeutics (Nasdaq: TGTX) with a Buy/Focus Pick rating and $33 price target following Q3 results and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
